De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Evoke Pharma Beheer

Beheer criteriumcontroles 3/4

De CEO Evoke Pharma's is Matt D'Onofrio, benoemd in Mar2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 857.37K, bestaande uit 52.5% salaris en 47.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.22% van de aandelen van het bedrijf, ter waarde $ 7.87K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 17.3 jaar.

Belangrijke informatie

Matt D'Onofrio

Algemeen directeur

US$857.4k

Totale compensatie

Percentage CEO-salaris	52.5%
Dienstverband CEO	less than a year
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	2.4yrs
Gemiddelde ambtstermijn bestuur	17.3yrs

Recente managementupdates

Recent updates

Evoke Pharma announces positive findings from second GIMOTI market research study

Jun 15

Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book

Jun 08

Evoke Pharma issued new U.S. patent covering methods of use for Gimoti

Jun 02

Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit

Mar 14

Analyse CEO-vergoeding

Hoe is Matt D'Onofrio's beloning veranderd ten opzichte van Evoke Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$857k	US$450k	-US$8m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$602k	US$417k	-US$8m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$1m	US$407k	-US$9m
Sep 30 2021	n/a	n/a	-US$9m
Jun 30 2021	n/a	n/a	-US$9m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$828k	US$387k	-US$13m
Sep 30 2020	n/a	n/a	-US$12m
Jun 30 2020	n/a	n/a	-US$12m
Mar 31 2020	n/a	n/a	-US$7m
Dec 31 2019	US$852k	US$372k	-US$7m
Sep 30 2019	n/a	n/a	-US$7m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$831k	US$357k	-US$8m
Sep 30 2018	n/a	n/a	-US$6m
Jun 30 2018	n/a	n/a	-US$10m
Mar 31 2018	n/a	n/a	-US$9m
Dec 31 2017	US$780k	US$345k	-US$12m

Compensatie versus markt: De totale vergoeding ($USD 857.37K ) Matt } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 667.78K ).

Compensatie versus inkomsten: De vergoeding van Matt is gestegen terwijl het bedrijf verliesgevend is.

CEO

Matt D'Onofrio (54 yo)

less than a year

Tenure

US$857,371

Compensatie

Mr. Matthew J. D'Onofrio, also known as Matt, MBA, had been the Chief Business Officer and Executive Vice President at Evoke Pharma, Inc. since 2010 until 2023. He served as Treasurer and Secretary since M...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Matthew D'Onofrio	Co-Founder	less than a year	US$857.37k	0.22% $ 8.1k
Marilyn Carlson	Chief Medical Officer	10.8yrs	US$728.49k	0.049% $ 1.8k
Mark Kowieski	Chief Financial Officer	less than a year	geen gegevens	0.057% $ 2.0k
Christopher Quesenberry	Chief Commercial Officer - Gimoti (TM)	4.2yrs	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EVOK wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Matthew D'Onofrio	Co-Founder	less than a year	US$857.37k	0.22% $ 8.1k
Kenneth Widder	Independent Director	17.3yrs	US$77.54k	0% $ 0
Todd Brady	Independent Director	17.3yrs	US$79.43k	0.0038% $ 136.3
Cam Garner	Independent Chairman of the Board	17.3yrs	US$102.95k	0.32% $ 11.4k
Malcolm Hill	Independent Director	17.3yrs	US$79.18k	0.018% $ 652.7
Vickie Reed	Independent Director	3.4yrs	US$85.31k	0% $ 0

17.3yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EVOK zijn ervaren en ervaren (gemiddelde ambtstermijn van 17.3 jaar).

Evoke Pharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Evoke Pharma, Inc., Annual General Meeting, May 22, 2024

Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024

Evoke Pharma, Inc. Announces Executive Changes

Insufficient new directors

Recent updates

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $1.921957 million.

New major risk - Share price stability

Consensus revenue estimates fall by 17%

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$0.08 loss, revenue downgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Evoke Pharma, Inc., Annual General Meeting, May 22, 2024

Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. Provides Earnings Guidance for 2024

Evoke Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Evoke Pharma, Inc. has completed a Follow-on Equity Offering.

Evoke Pharma Announces Update on Non-Compliance Notice from Nasdaq

Evoke Pharma Receives Notice from Nasdaq

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.71 loss in 2Q 2022)

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI

Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain Compliance

Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Consensus EPS estimates fall by 13%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 57%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Evoke Pharma, Inc. Announces Executive Changes

Evoke Pharma, Inc. Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

Price target decreased to US$7.00

Consensus revenue estimates increase by 25%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Evoke Pharma, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Evoke Pharma, Inc. announces United States Patent and Trademark Office Issues Notice of Allowance for the its Product, GIMOTI® (Metoclopramide) Nasal Spray

Evoke to get US patent for nasal spray Gimoti

Consensus revenue estimates fall by 19%

Price target decreased to US$63.50

Evoke Pharma Q2 GAAP loss per share narrows, revenue up

Evoke Pharma, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Evoke Pharma, Inc. Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use

Evoke Pharma gets Canadian patent linked to Gimoti nasal spray

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

Evoke Pharma, Inc. Announces Real-World Data Analysis Reveals Lower Risk of Tardive Dyskinesia with Metoclopramide Than Previously Reported

Price target decreased to US$6.50

Evoke Pharma, Inc. Announces Positive Findings from the First Patient-Centered Survey Related to GIMOTI®

Consensus EPS estimates fall by 29%

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target increased to US$9.50

Evoke Pharma Granted FDA Market Exclusivity for Gimoti®

Evoke Pharma, Inc. Announces Approval of GIMOTI to the Texas Medicaid Preferred Drug List

Insufficient new directors

Consensus forecasts updated

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Evoke Pharma, Inc. Announces Positive Outcomes from an Additional Research Study Conducted for GIMOTI

Price target increased to US$9.50

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Consensus revenue estimates increase to US$1.28m

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Evoke Pharma, Inc. Announces Positive Findings from A Second Market Research Study Conducted for Gimoti® (Metoclopramide) Nasal Spray

Evoke Pharma announces positive findings from second GIMOTI market research study

Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book

Evoke Pharma issued new U.S. patent covering methods of use for Gimoti